Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients

K. Kluckova, J. Kozak, K. Szaboova, B. Rychly, M. Svajdler, M. Suchankova, E. Tibenska, B. Filova, J. Steno, V. Matejcik, M. Homolova, M. Bucova

. 2020 ; 2020 (-) : 1798147. [pub] 20200701

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020406

Objective: In recent years, the role of the modern inflammatory markers TREM-1 (triggering receptors expressed on myeloid cells) and HMGB1 (high mobility group box 1 protein) in tumorigenesis has begun to be studied. Their role in gliomas is not clear. The aim of our study was to find the role of inflammation in gliomas. Patients and Methods. In 63 adult patients with gliomas and 31 healthy controls, the expressions of TREM-1 and TREM-2 on CD14+ blood cells (method: flow cytometry) and the levels of soluble sTREM-1, HMGB1, IL-6, and IL-10 (Elisa tests) were analyzed. Results: Cox proportional hazard analysis showed that a TREM-1/TREM-2 ratio was associated with reduced overall survival (HR = 1.001, P = 0.023). Patients with a TREM-1/TREM-2 ratio above 125 survived significantly shorter than patients with a TREM-1/TREM-2 ratio below 125. The percentage of CD14+ TREM-1+ cells was strongly associated with a plasma IL-6/IL-10 ratio (positively) and with IL-10 (negatively). Conversely, we found a higher percentage of CD14+ TREM-2+ monocytes in better surviving patients; these cells could downregulate the exaggerated inflammation and potentiate the phagocytosis in the tumor. The serum levels of HMGB1 negatively correlated with the percentage of CD14+ TREM-1+ cells and with the TREM-1/TREM-2 ratio. The positive correlation between the serum levels of a late proinflammatory cytokine HMGB1 with the percentage of TREM2+ CD14+ monocytes can be explained as an effort for suppression of systemic inflammation by anti-inflammatory acting CD14+ TREM-2+ cells. Conclusion: We showed that the TREM-1/TREM-2 ratio (expression on the surface of blood monocytes) could help predict prognosis in patients with gliomas, especially in high-grade gliomas, and that systemic inflammation has an impact on the patient's overall survival. This is the first study that showed that TREM expression on monocytes in peripheral blood could help predict prognosis in patients with gliomas.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020406
003      
CZ-PrNML
005      
20240903122625.0
007      
ta
008      
210728e20200701xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2020/1798147 $2 doi
035    __
$a (PubMed)32684831
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kluckova, K $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
245    10
$a TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients / $c K. Kluckova, J. Kozak, K. Szaboova, B. Rychly, M. Svajdler, M. Suchankova, E. Tibenska, B. Filova, J. Steno, V. Matejcik, M. Homolova, M. Bucova
520    9_
$a Objective: In recent years, the role of the modern inflammatory markers TREM-1 (triggering receptors expressed on myeloid cells) and HMGB1 (high mobility group box 1 protein) in tumorigenesis has begun to be studied. Their role in gliomas is not clear. The aim of our study was to find the role of inflammation in gliomas. Patients and Methods. In 63 adult patients with gliomas and 31 healthy controls, the expressions of TREM-1 and TREM-2 on CD14+ blood cells (method: flow cytometry) and the levels of soluble sTREM-1, HMGB1, IL-6, and IL-10 (Elisa tests) were analyzed. Results: Cox proportional hazard analysis showed that a TREM-1/TREM-2 ratio was associated with reduced overall survival (HR = 1.001, P = 0.023). Patients with a TREM-1/TREM-2 ratio above 125 survived significantly shorter than patients with a TREM-1/TREM-2 ratio below 125. The percentage of CD14+ TREM-1+ cells was strongly associated with a plasma IL-6/IL-10 ratio (positively) and with IL-10 (negatively). Conversely, we found a higher percentage of CD14+ TREM-2+ monocytes in better surviving patients; these cells could downregulate the exaggerated inflammation and potentiate the phagocytosis in the tumor. The serum levels of HMGB1 negatively correlated with the percentage of CD14+ TREM-1+ cells and with the TREM-1/TREM-2 ratio. The positive correlation between the serum levels of a late proinflammatory cytokine HMGB1 with the percentage of TREM2+ CD14+ monocytes can be explained as an effort for suppression of systemic inflammation by anti-inflammatory acting CD14+ TREM-2+ cells. Conclusion: We showed that the TREM-1/TREM-2 ratio (expression on the surface of blood monocytes) could help predict prognosis in patients with gliomas, especially in high-grade gliomas, and that systemic inflammation has an impact on the patient's overall survival. This is the first study that showed that TREM expression on monocytes in peripheral blood could help predict prognosis in patients with gliomas.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gliom $x krev $x metabolismus $x mortalita $7 D005910
650    _2
$a protein HMGB1 $x krev $7 D024243
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-10 $x krev $7 D016753
650    _2
$a interleukin-6 $x krev $7 D015850
650    _2
$a lipopolysacharidové receptory $x metabolismus $7 D018950
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové glykoproteiny $x metabolismus $7 D008562
650    _2
$a lidé středního věku $7 D008875
650    _2
$a monocyty $x metabolismus $7 D009000
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a receptory imunologické $x metabolismus $7 D011971
650    _2
$a receptor TREM-1 $x metabolismus $7 D000073871
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kozak, J $u Department of Neurosurgery, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
700    1_
$a Szaboova, K $u Medirex, Ltd., Bratislava, Slovakia
700    1_
$a Rychly, B $u Alpha Medical, Ltd., Bratislava, Slovakia
700    1_
$a Svajdler, M $u Cytopathos, Ltd., Bratislava, Slovakia $u Sikl's Department of Pathology, Charles University, The Faculty of Medicine and Faculty Hospital in Pilsen, Czech Republic
700    1_
$a Suchankova, M $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Tibenska, E $u Medirex, Ltd., Bratislava, Slovakia
700    1_
$a Filova, B $u Institute of Medical Physics, Biophysics, Informatics and Telemedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Steno, J $u Department of Neurosurgery, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
700    1_
$a Matejcik, V $u Department of Neurosurgery, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
700    1_
$a Homolová, Monika, $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia $d 1975- $7 xx0322165
700    1_
$a Bucova, M $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
773    0_
$w MED00006378 $t Mediators of inflammation $x 1466-1861 $g Roč. 2020 (20200701), s. 1798147
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32684831 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20240903122622 $b ABA008
999    __
$a ok $b bmc $g 1691058 $s 1140852
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 2020 $c - $d 1798147 $e 20200701 $i 1466-1861 $m Mediators of inflammation $n Mediators Inflamm $x MED00006378
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace